Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Drug giant Pfizer will partner with Sangamo Therapeutics to develop a gene therapy for the neurodegenerative disorders amyotrophic lateral sclerosis and frontotemporal lobar degeneration. The therapy will use a zinc finger protein to bind a region of mutant DNA implicated in familial versions of the diseases. When the zinc finger is present, a second protein attached to it shuts down expression of the disease-causing gene. Sangamo will receive $12 million up front and potential milestones of up to $150 million.
This article has been sent to the following recipient: